Jane Buckner, MD
Rheumatology · Seattle, WANPI 1740399872
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,085 of the $57,136 with a category attached, or 91.2%. E.r. Squibb & Sons, L.L.C. accounts for 74.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $23,262 and has fallen 87.3% since, to $2,949 in 2025. Among rheumatology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $1360.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$43K
- Modernatx, Inc.$7K
- Janssen Global Services, LLC$4K
- Merck$3K
- Biogen$225
- Regeneron$149
- plus $95 from 1 others
Across 7 payments — averaging $245,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.7M
- Pfizer$57K
What the payments were for
- Consulting fees$52,08591%
- Travel & lodging$3,9997%
- Food & beverage$1,0522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 31 | $42,803 |
| Modernatx, Inc. | 5 | $6,969 |
| Janssen Global Services, LLC | 2 | $4,320 |
| Merck | 1 | $2,575 |
| Biogen | 1 | $225 |
| Regeneron | 1 | $149 |
| Janssen Research & Development, LLC | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,136 in reported general payments places this provider in the 90th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $79,674 |
| Hydroxychloroquine Sulfate | 47 | $3,208 |
| Azathioprine | 12 | $999 |
| MethotrexateMethotrexate Sodium | 26 | $922 |
| Prednisone | 84 | $764 |
| Sulfasalazine | 24 | $586 |
| Meloxicam | 12 | $124 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Seattle
- Stanford PengSeattle$3.5M
- Philip MeaseSeattle$2.1M
- Steven OvermanSeattle$17K
- Anthony KrajcerSeattle$14K
- Amish DaveSeattle$13K
- Namrata SinghSeattle$13K
- Peter MohaiSeattle$12K
- Myriam GuevaraSeattle$12K
- Kwang Hoon HanSeattle$11K
- Jeffrey CarlinSeattle$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.